At a glance
The Arthritis Translational Research Award funds high-impact translational and preclinical research on arthritis that is meant to move findings toward clinically relevant solutions. It is open to eligible U.S. Department of War organizations, including intramural and extramural, domestic and foreign, for-profit and nonprofit, and public or private entities; independent investigators at eligible organizations may serve as principal investigator. The program expects about $1.6 million total to fund about two awards, with a total cost cap of $800,000 per award and a maximum performance period of 3 years. Cost sharing is not required. Clinical trials and basic research are not allowed, and applications must fit one of the listed focus areas and arthritis types.
What it funds
Official description from grants.gov
Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions. Research funded under this award mechanism will be hypothesis-driven, high-impact applied research that is relevant to Service Members, Veterans, their Families and the American public. Research addressing any and all types of arthritis is encouraged. Distinctive Features: The FY26 ATRP TRA mechanism is intended to support preclinical or animal research and may not be used for clinical research or clinical trials. Basic research, as defined in Section 3.1.2, is not allowed. A key aspect of this award mechanism is impact. The application should explicitly state how outcomes of the proposed research will significantly advance arthritis research, particularly in accelerating critical findings into clinically relevant solutions. Preliminary and/or published data, originating from research conducted by the applicant(s) or others, is required.
Who can apply
- Unrestricted